ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Investing in stocks is risky and each stock can have its own set of risks. Below is a list of risks that generally apply to all stocks:

Volatility: The performance of stocks can be volatile, with their value dropping as quickly as it can rise. You should be prepared to lose all the money you invest in stocks.

Liquidity: Some stocks may suffer from low liquidity which could prevent you buying or selling them at the price you want or expect.

Complexity: Specific stocks and ETFs may carry with them specific complex risks that are hard to understand. Do your own research and if something sounds too good to be true, it probably is.

Don’t put all your eggs in one basket: Putting all your money into a single type of investment is risky. Spreading your money across different investments makes you less dependent on any one to do well.

If you want to learn more about specific risks related to equity securities, please visit our dedicated equities disclosure page.